Page last updated: 2024-11-05

clofenapate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Clofenapate is a non-steroidal anti-inflammatory drug (NSAID) that is a prodrug of clofenamic acid. It is used for the treatment of pain and inflammation, particularly in the musculoskeletal system. Clofenapate is absorbed from the gastrointestinal tract and rapidly hydrolyzed to clofenamic acid, which is the active form of the drug. Clofenamic acid is a potent inhibitor of cyclooxygenase (COX), the enzyme that produces prostaglandins, which are involved in inflammation and pain. It has been studied for its potential to reduce inflammation and pain in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. However, due to its potential for gastrointestinal side effects, it has been largely replaced by other NSAIDs with better safety profiles. Clofenapate is still used in some countries for the treatment of pain and inflammation.'

Clofenapate: An oral hypolipemic agent primarily used in DOGS and RATS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID30602
SCHEMBL ID11684008
MeSH IDM0004581

Synonyms (19)

Synonym
21340-68-1
methyl clofenapate
methyl 2-[(4'-chlorobiphenyl-4-yl)oxy]-2-methylpropanoate
clofenapate
brn 2139378
propanoic acid, 2-((4'-chloro(1,1'-biphenyl)-4-yl)oxy)-2-methyl-, methyl ester
methyl-2-(4-(p-chlorophenyl)phenoxy)-2-methylpropionate
ccris 388
ici 54856 methyl ester
propionic acid, 2-((4'-chloro-4-biphenylyl)oxy)-2-methyl-, methyl ester
methyl 2-[4-(4-chlorophenyl)phenoxy]-2-methylpropanoate
unii-f54j2wv8px
f54j2wv8px ,
propanoic acid, 2-[(4'-chloro[1,1'-biphenyl]-4-yl)oxy]-2-methyl-, methyl ester
ici-54856 methyl ester
SCHEMBL11684008
DTXSID8020836
methyl-2-[4-(p-chloro-phenyl)-phenoxy]-2-methyl-propionate
Q27277652

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Methyl clofenapate was not toxic up to a dose that produced precipitate, so cannot be directly compared with WY, which induced aberrations only at toxic dose levels."( The genetic toxicity of the peroxisome proliferator class of rodent hepatocarcinogen.
Armstrong, MJ; Ashby, J; Galloway, SM; Johnson, TE, 2000
)
0.74

Dosage Studied

Methylclofenapate (MCP) is a potent peroxisome proliferator. Snell dwarf mice were dosed with MCP at daily intervals by gavage (25 mg/kg)

ExcerptRelevanceReference
" Groups of three rats were dosed daily by gavage with methylclofenapate at 25 mg/kg in 5 ml/kg corn oil for nine weeks, or were administered a vehicle control."( Differential tissue-specific expression and induction of cytochrome P450IVA1 and acyl-CoA oxidase.
Bars, RG; Bell, DR; Elcombe, CR, 1992
)
0.53
" Dosing was interrupted for 28, 35, 56, 70 or 84 days and then resumed (25 mg/kg by gavage at 0 and 24 h)."( Recovery of hyperplastic responsiveness in rat liver after dosing with the peroxisome proliferator methylclofenapate.
Bybee, A; Elcombe, CR; Kelly, MD; Pritchard, NR; Styles, JA, 1991
)
0.5
" In this study, rats were dosed intraperitoneally with the potent peroxisome proliferator methylclofenapate and the hepatic induction response was studied."( Localization and differential induction of cytochrome P450IVA and acyl-CoA oxidase in rat liver.
Bars, RG; Bell, DR; Elcombe, CR; Gibson, GG, 1991
)
0.5
"Both Snell dwarf mice (dw/dw) and their phenotypically normal heterozygotes (dw/+) were dosed with methylclofenapate (MCP) at daily intervals by gavage (25 mg/kg)."( Effects produced by the non-genotoxic hepatocarcinogen methylclofenapate in dwarf mice: peroxisome induction uncoupled from DNA synthesis and nuclearity changes.
Foster, JR; Kelly, MD; Pritchard, NR; Styles, JA, 1990
)
0.73
" We have reported previously that 7-day dosing with DEHP induced a higher bromodeoxyuridine labeling index (LI) in binuclear octoploid (2x4N) rat hepatocytes than did DCB, suggesting that induction of DNA synthesis in 2x4N hepatocytes might represent a more substantial carcinogenic risk."( The nongenotoxic hepatocarcinogens diethylhexylphthalate and methylclofenapate induce DNA synthesis preferentially in octoploid rat hepatocytes.
Hasmall, SC; Roberts, RA,
)
0.37
" Liver mRNA was isolated from rats dosed with six different chemicals, dexamethasone, troleandomycin, miconazole, clotrimazole, and methylclofanapate, which are all known to induce different cytochrome P450 genes, and isoniazid, which does not cause histopathological changes."( An evaluation of a low-density DNA microarray using cytochrome P450 inducers.
Bertholet, V; Bonnert, TP; de Longueville, F; Dos Santos-Mendes, S; Evrard, S; Jack, A; Meneses-Lorente, G; Pike, A; Remacle, J; Scott-Stevens, P; Sohal, B, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (27.45)18.7374
1990's30 (58.82)18.2507
2000's7 (13.73)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.46 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]